| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 9305- | MushMait, | Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling |
| - | vitro+vivo, | sarcoma, | NA |
| 5611- | NaHCO3, | NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells |
| - | vitro+vivo, | HCC, | HepG2 |
| 5598- | NaHCO3, | Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases |
| - | in-vivo, | BC, | MDA-MB-231 |
| 5620- | NaHCO3, | Tumor acidity: From hallmark of cancer to target of treatment |
| - | Review, | Var, | NA |
| 5616- | NaHCO3, | DCA, | Bicarbonate and dichloroacetate: Evaluating pH altering therapies in a mouse model for metastatic breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 5614- | NaHCO3, | Targeting the Acidic Tumor Microenvironment: Unexpected Pro-Neoplastic Effects of Oral NaHCO3 Therapy in Murine Breast Tissue |
| - | in-vivo, | BC, | NA |
| 5613- | NaHCO3, | The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion |
| - | Study, | Var, | NA |
| 5612- | NaHCO3, | immuno, | Neutralization of tumor acidity improves anti-tumor responses to immunotherapies |
| - | vitro+vivo, | Var, | B16-F10 |
| 5599- | NaHCO3, | Acidity generated by the tumor microenvironment drives local invasion |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
| 5608- | NaHCO3, | Sodium Bicarbonate Nanoparticles for Amplified Cancer Immunotherapy by Inducing Pyroptosis and Regulating Lactic Acid Metabolism |
| - | Study, | Var, | NA |
| 5607- | NaHCO3, | Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review |
| - | Review, | Var, | NA |
| 5602- | NaHCO3, | immuno, | Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model |
| - | in-vivo, | BC, | 4T1 |
| 5600- | NaHCO3, | Acidosis and Cancer: from Mechanism to Neutralization |
| - | Review, | Var, | NA |
| 1797- | NarG, | Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 1269- | NCL, | Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway |
| - | in-vitro, | Pca, | DU145 |
| 1271- | NCL, | Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 6489- | Nimb, | Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model |
| - | in-vivo, | Pca, | DU145 | - | in-vivo, | Pca, | LNCaP |
| 6485- | Nimb, | Limonoids from neem (Azadirachta indica A. Juss.) are potential anticancer drug candidates |
| - | Review, | Var, | NA |
| 6493- | Nimb, | Nimbolide, a Limonoid Triterpene, Inhibits Growth of Human Colorectal Cancer Xenografts by Suppressing the Proinflammatory Microenvironment |
| - | in-vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | HT29 |
| 4977- | Nimb, | Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis |
| - | vitro+vivo, | PC, | AsPC-1 | - | in-vitro, | PC, | PANC1 |
| 1911- | Nos, | Noscapine inhibits tumor growth in TMZ-resistant gliomas |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 968- | OA, | Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MBT-2 |
| 1229- | OA, | Review of the Clinical Effect of Orlistat |
| - | Review, | Var, | NA |
| 4629- | OLE, | Oleuropein exhibits anticancer effects by inducing apoptosis and inhibiting cell motility in MCF7 and MDA-MB231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MCF7 |
| 4627- | OLE, | Oleuropein regulates ubiquitination-mediated Mcl-1 turnover and exhibits antitumor activity |
| - | in-vitro, | Oral, | NA |
| 1045- | OLST, | Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line |
| - | in-vitro, | AML, | Jurkat |
| 1227- | OLST, | Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling |
| - | in-vivo, | CRC, | NA |
| 8425- | OM, | Anti-metastatic and anti-tumor growth effects of Origanum majorana on highly metastatic human breast cancer cells: inhibition of NFκB signaling and reduction of nitric oxide production |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8435- | OM, | Aroma, | Memory-Enhancing Effects of Origanum majorana Essential Oil in an Alzheimer's Amyloid beta1-42 Rat Model: A Molecular and Behavioral Study |
| - | in-vivo, | AD, | NA |
| 8430- | OM, | T4O, | Exploring the Anticancer Potential of Origanum majorana Essential Oil Monoterpenes Alone and in Combination against Non-Small Cell Lung Cancer |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | LNM35 |
| 8429- | OM, | Origanum majorana essential oil decreases lung tumor growth and metastasis in vitro and in vivo |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | LNM35 |
| 1812- | Oxy, | Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA | - | in-vitro, | NA, | BEAS-2B |
| 9044- | PatchO, | Patchouli oil and its main component patchouli alcohol inhibit colorectal cancer by activating ectopic olfactory receptor |
| - | vitro+vivo, | CRC, | HCT116 |
| 9046- | PatchO, | Patchouli alcohol suppresses castration-resistant prostate cancer progression by inhibiting NF-κB signal pathways |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 9047- | PatchO, | Patchouli alcohol, an essential oil of Pogostemon cablin, exhibits anti-tumorigenic activity in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HUVECs |
| 2070- | PB, | Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 2059- | PB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 2069- | PB, | Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes |
| - | in-vitro, | Tong, | NA |
| 2074- | PB, | Chemo, | The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | H1650 |
| 2077- | PB, | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 2027- | PB, | Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors |
| - | Trial, | Var, | NA |
| 2036- | PB, | Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 2037- | PB, | Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 2045- | PB, | Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | LN-18 |
| 8982- | PCorn, | Purple corn color inhibition of prostate carcinogenesis by targeting cell growth pathways |
| - | vitro+vivo, | Pca, | LNCaP |
| - | in-vitro, | Pca, | DU145 |
| 4947- | PEITC, | Phenethyl Isothiocyanate (PEITC) Inhibits the Growth of Human Oral Squamous Carcinoma HSC-3 Cells through G0/G1 Phase Arrest and Mitochondria-Mediated Apoptotic Cell Death |
| - | in-vitro, | Oral, | HSC3 |
| 4948- | PEITC, | Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo |
| - | vitro+vivo, | Oral, | CAL27 | - | vitro+vivo, | Oral, | FaDu | - | vitro+vivo, | Oral, | SCC4 | - | vitro+vivo, | Oral, | SCC9 |
| 4951- | PEITC, | ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis |
| - | in-vitro, | Ovarian, | PA1 | - | in-vitro, | Ovarian, | SKOV3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:323 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid